Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$2.85, compared with -$0.66 a year earlier. Trailing-twelve-month EPS (Diluted) was -$4.24.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 6 analysts of -$2.31 (-0.9%) for the fiscal year ending Dec 2026, a slowdown from the +37.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$2.85-506.4% QoQ
- Last fiscal yearDec 2025
- -$2.29+37.4% YoY
- LTMJun 2026
- -$4.24-19.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -331.8% | -9.9% | +321.9 pp |
| 1 year | +37.4% | -0.9% | -38.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.29) USD
- Year-over-year change
- +37.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.29) | +37.4% |
| FY2024 | 2024-12-31 | (3.66) | -83.9% |
| FY2023 | 2023-12-31 | (1.99) | +65.5% |
| FY2022 | 2022-12-31 | (5.77) | -48.3% |
| FY2021 | 2021-12-31 | (3.89) | — |
EPS (Diluted) vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 EPS (Diluted) of -$4.24 is the 6th highest of the 7 companies compared; the peer median is -$1.64.
- Its year-over-year change of -19.1% is the 4th highest of 7, against a peer median of -27.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.71 | -10.9% | — | |
| LTM Mar 2026 | -$1.42 | +19.8% | — | |
| LTM Sep 2026 | -$1.56 | -43.1% | — | |
| LTM Mar 2026 | -$1.71 | +45.1% | — | |
| LTM Mar 2026 | -$2.75 | -4396.9% | — | |
| LTM Jun 2026 | -$4.24 | -19.1% | — | |
| LTM Jun 2026 | -$5.86 | -58.0% | — | |
| Peer median (excluding MLYS) | -$1.64 | -27.0% | — | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| Weighted Avg Shares | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
| Weighted Avg Shares (Diluted) | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.